Involvement of p53 function in different magnitude of genotoxic and cytotoxic responses in in vitro micronucleus assays

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 726, Issue 1, 2011, Pages 21-28

  Hashimoto, Kiyohiro ^a   Nakajima, Yumi ^a   Uematsu, Rieko ^a   Matsumura, Shigeo ^a   Chatani, Fumio ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Human cells; In vitro micronucleus assay; NH32; P53; Rodent cells; TK6

Indexed keywords

ANEUGEN; APHIDICOLIN; BLEOMYCIN; CLASTOGEN; CYTARABINE; DEMECOLCINE; HYDROXYUREA; MESYLIC ACID METHYL ESTER; MITOMYCIN C; PACLITAXEL; PROTEIN P53; TIABENDAZOLE; VINCRISTINE SULFATE; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS CELL; LYMPHOBLASTOID CELL; MICRONUCLEUS TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; CELL LINE; CELL SURVIVAL; CRICETINAE; CRICETULUS; DNA DAMAGE; HUMANS; LYMPHOCYTES; MICRONUCLEUS TESTS; MUTAGENS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

CRICETULUS GRISEUS; RODENTIA;

EID: 80053620116     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2011.07.009     Document Type: Article

References (43)

1. OECD, In vitro Mammalian Cell Micronucleus Test (MNvit). OECD Guideline for Testing of Chemicals. No. 487, OECD, Paris, 2010, Available at: http://www.oecd.org/env/testguidelines.
2. Le Fevre A.C., Boitier E., Marchandeau J.P., Sarasin A., Thybaud V. Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat. Res. 2007, 619:16-29.
3. Aardema M.J., Snyder R.D., Spicer C., Divi K., Morita T., Mauthe R.J., Gibson D.P., Soelter S., Curry P.T., Thybaud V., Lorenzon G., Marzin D., Lorge E. SFTG international collaborative study on the in vitro micronucleus test. III. Using CHO cells. Mutat. Res. 2006, 607:61-87.
4. Matsushima T., Hayashi M., Matsuoka A., Ishidate M., Miura K.F., Shimizu H., Suzuki Y., Morimoto K., Ogura H., Mure K., Koshi K., Sofuni T. Validation study of the in vitro micronucleus test in a Chinese hamster lung cell line (CHL/IU). Mutagenesis 1999, 14:569-580.
5. Wakata A., Matsuoka A., Yamakage K., Yoshida J., Kubo K., Kobayashi K., Senjyu N., Itoh S., Miyajima H., Hamada S., Nishida S., Araki H., Yamamura E., Matsui A., Thybaud V., Lorenzon G., Marzin D., Lorge E. SFTG international collaborative study on in vitro micronucleus test IV. Using CHL cells. Mutat. Res. 2006, 607:88-124.
6. Oliver J., Meunier J.R., Awogi T., Elhajouji A., Ouldelhkim M.C., Bichet N., Thybaud V., Lorenzon G., Marzin D., Lorge E. SFTG international collaborative study on in vitro micronucleus test V. Using L5178Y cells. Mutat. Res. 2006, 607:125-152.
7. Elhajouji A. Mitomycin C, 5-fluoruracil, colchicine and etoposide tested in the in vitro mammalian cell micronucleus test (MNvit) in the human lymphoblastoid cell line TK6 at Novartis in support of OECD draft Test Guideline 487. Mutat. Res. 2010, 702:157-162.
8. Fellows M.D., O'Donovan M.R. Etoposide, cadmium chloride, benzo[a]pyrene, cyclophosphamide and colchicine tested in the in vitro mammalian cell micronucleus test (MNvit) in the presence and absence of cytokinesis block using L5178Y mouse lymphoma cells and 2-aminoanthracene tested in MNvit in the absence of cytokinesis block using TK6 cells at AstraZeneca UK, in support of OECD draft Test Guideline 487. Mutat. Res. 2010, 702:163-170.
9. Fowler P., Whitwell J., Jeffrey L., Young J., Smith K., Kirkland D. Cadmium chloride, benzo[a]pyrene and cyclophosphamide tested in the in vitro mammalian cell micronucleus test (MNvit) in the human lymphoblastoid cell line TK6 at Covance laboratories, Harrogate UK in support of OECD draft Test Guideline 487. Mutat. Res. 2010, 702:171-174.
10. Nesslany F., Marzin D. Cytosine arabinoside, vinblastine, diethylstilbestrol and 2-aminoanthracene tested in the in vitro human TK6 cell line micronucleus test (MNvit) at Institut Pasteur de Lille in support of OECD draft test guideline 487. Mutat. Res. 2010, 702:212-218.
11. Schuler M., Gudi R., Cheung J., Kumar S., Dickinson D., Engel M., Szkudlinska A., Colman M., Maduka N., Sherman J., Thiffeault C. Evaluation of phenolphthalein, diazepam and quinacrine dihydrochloride in the in vitro mammalian cell micronucleus test in Chinese hamster ovary (CHO) and TK6 cells. Mutat. Res. 2010, 702:219-229.
12. Kirkland D. Evaluation of different cytotoxic and cytostatic measures for the in vitro micronucleus test (MNVit): summary of results in the collaborative trial. Mutat. Res. 2010, 702:139-147.
13. Schwartz J.L., Jordan R., Sedita B.A., Swenningson M.J., Banath J.P., Olive P.L. Different sensitivity to cell killing and chromosome mutation induction by gamma rays in two human lymphoblastoid cell lines derived from a single donor: possible role of apoptosis. Mutagenesis 1995, 10:227-233.
14. Donner E.M., Preston R.J. The relationship between p53 status, DNA repair and chromatid aberration induction in G2 mouse embryo fibroblast cells treated with bleomycin. Carcinogenesis 1996, 17:1161-1165.
15. Schwartz J.L., Jordan R. Selective elimination of human lymphoid cells with unstable chromosome aberrations by p53-dependent apoptosis. Carcinogenesis 1997, 18:201-205.
16. Greenwood S.K., Armstrong M.J., Hill R.B., Bradt C.I., Johnson T.E., Hilliard C.A., Galloway S.M. Fewer chromosomal aberrations and earlier apoptosis induced by DNA synthesis inhibitors, a topoisomerase II inhibitor or alkylating agents in human cells with normal compared with mutant p53. Mutat. Res. 1998, 401:39-53.
17. Honma M., Hayashi M. Comparison of in vitro micronucleus and gene mutation assay results for p53-competent versus p53-deficient human lymphoblastoid cells. Environ. Mol. Mutagen 2010, (Oct. 20 Epub ahead of print).
18. Chuang Y.Y., Chen Q., Brown J.P., Sedivy J.M., Liber H.L. Radiation-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells. Cancer Res. 1999, 59:3073-3076.
19. Hilliard C., Hill R., Armstrong M., Fleckenstein C., Crowley J., Freeland E., Duffy D., Galloway S.M. Chromosome aberrations in Chinese hamster and human cells: a comparison using compounds with various genotoxicity profiles. Mutat. Res. 2007, 616:103-118.
20. Kirkland D., Pfuhler S., Tweats D., Aardema M., Corvi R., Darroudi F., Elhajouji A., Glatt H., Hastwell P., Hayashi M., Kasper P., Kirchner S., Lynch A., Marzin D., Maurici D., Meunier J.R., Müller L., Nohynek G., Parry J., Parry E., Thybaud V., Tice R., van Benthem J., Vanparys P., White P. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. Mutat. Res. 2007, 628:31-55.
21. Tsutsui T., Suzuki N., Maizumi H., Barrett J.C. Aneuploidy induction in human fibroblasts: comparison with results in Syrian hamster fibroblasts. Mutat. Res. 1990, 240:241-249.
22. Hilliard C.A., Armstrong M.J., Bradt C.I., Hill R.B., Greenwood S.K., Galloway S.M. Chromosome aberrations in vitro related to cytotoxicity of nonmutagenic chemicals and metabolic poisons. Environ. Mol. Mutagen 1998, 31:316-326.
23. Lorge E. Comparison of different cytotoxicity measurements for the in vitro micronucleus assay using L5178Y and TK6 cells in support of OECD draft Test Guideline 487. Mutat. Res. 2010, 702:199-207.
24. Hu T., Miller C.M., Ridder G.M., Aardema M.J. Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: implications for genotoxicity testing. Mutat. Res. 1999, 426:51-62.
25. Sionov R.V., Haupt Y. The cellular response to p53: the decision between life and death. Oncogene 1999, 18:6145-6157.
26. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
27. Albrechtsen N., Dornreiter I., Grosse F., Kim E., Wiesmüller L., Deppert W. Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene 1999, 18:7706-7717.
28. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
29. Honma M., Hayashi M., Sofuni T. Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53-mutated human lymphoblastoid cells. Mutat. Res. 1997, 374:89-98.
30. Doerr C.L., Harrington-Brock K., Moore M.M. Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells. Mutat. Res. 1998, 222:191-203.
31. Yu Y., Li C.Y., Little J.B. Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells. Oncogene 1997, 14:1661-1667.
32. Vukicevic V., Kampfinger K., Stopper H. Influence of altered apoptosis in human lymphoblastoid cell lines on micronucleus frequency. Toxicol. Lett. 2004, 147:187-195.
33. Goh A.M., Coffill C.R., Lane D.P. The role of mutant p53 in human cancer. J. Pathol. 2011, 223:116-126.
34. Vernole P., Tedeschi B., Tentori L., Levati L., Argentin G., Cicchetti R., Forini O., Graziani G., D'Atri D. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin. Mutat. Res. 2006, 594:63-77.
35. Steinmann K.E., Belinsky G.S., Lee D., Schlegel R. Chemically induced premature mitosis: differential response in rodent and human cells and the relationship to cyclin B synthesis and p34cdc2/cyclin B complex formation. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:6843-6847.
36. Kung A.L., Sherwood S.W., Schimke R.T. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:9553-9557.
37. Jha A.N., Hande P.M., Mullenders L.H., Natarajan T.T. Mimosine is a potent clastogen in primary and transformed hamster fibroblasts but not in primary or transformed human lymphocytes. Mutagenesis 1995, 10:385-391.
38. Schimke R.T., Kung A.L., Rush D.F., Sherwood S.W. Differences in mitotic control among mammalian cells. Cold Spring Harb. Symp. Quant. Biol. 1991, 56:417-425.
39. Haller K., Kibler K.V., Kasai T., Chi Y.H., Peloponese J.M., Yedavalli V.S., Jeang K.T. The N-terminus of rodent and human MAD1 confers species-specific stringency to spindle assembly checkpoint. Oncogene 2006, 25:2137-2147.
40. Van Hummelen P., Elhajouji A., Kirsch-Volders M. Clastogenic and aneugenic effects of three benzimidazole derivatives in the in vitro micronucleus test using human lymphocytes. Mutagenesis 1995, 10:23-29.
41. Stern M., Cid M.G., Larripa I., Slavutsky I. AZT-induction of micronuclei in human lymphocyte subpopulations. Toxicol. Lett. 1994, 70:235-242.
42. González Cid M., Larripa I. Genotoxic activity of azidothymidine (AZT) in in vitro systems. Mutat. Res. 1994, 321:113-118.
43. Aruna R.R., Jagetia G.C. Azidothymidine induces dose dependent increase in micronuclei formation in cultured HeLa cells. Pharmazie 2001, 56:492-500.